Farallon Capital Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Farallon Capital Management’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-84,502	Closed	-$280K	–	129
2020 Q1	$280K	Sell	84,502 -915,498	-92%	-$4.19M	﹤0.01%	102
2019 Q4	$6.11M	Buy	1,000,000 +192,072	+24%	+$791K	0.04%	107
2019 Q3	$3.37M	Buy	807,928 +50,967	+7%	+$406K	0.03%	94
2019 Q2	$9.93M	Buy	+756,961	New	+$9.28M	0.06%	87

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Farallon Capital Management's PHAS Position: Q2 2020 in Review

Farallon Capital Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2020, closing a stake of 84,502 shares — an estimated $280K sold.

Farallon Capital Management first reported a position in PHAS in Q2 2019 and held it in 4 quarters. The position peaked at $9.93M in Q2 2019. 60 funds tracked by Wall St. Rank hold PHAS as of Q2 2020.

Farallon Capital Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Farallon Capital Management sold 84,502 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $280K.
Farallon Capital Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
Farallon Capital Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $9.93M in Q2 2019.
60 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Farallon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.